BridgeMD
New treatment option for Allergic Rhinitis
Official title Study of Stapokibart Injection in Patients With Allergic Rhinitis
ClinicalTrials.gov ID: NCT06525597
What this study is testing
What is Stapokibart Injection?
Stapokibart Injection is an investigational medicine, given as an injectable medicine, being studied as a potential treatment for allergic rhinitis.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is a Randomized, Double-blind, Placebo-controlled phase II clinical study evaluating the efficacy and safety of Stapokibart injection in patients with allergic rhinitis.
- Phase 2: a mid-size study of how well it works
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance. You may not know which one you got.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 12 to 65
You may be able to join if
- Able to understand the study and voluntarily sign the Informed consent form.
- Diagnosed Allergic Rhinitis according to the Criteria stated in the Chinese Guidelines for the Diagnosis and Treatment of Allergic Rhinitis (2022...
- people with asthma must be evaluated by the researcher as having a stable condition.
- Has a positive skin prick test (SPT) or positive antigen-specific serum immunoglobulin E (IgE).
You likely can't join if
- Use of anti-interleukin 4 receptor alpha subunit (IL-4Rα) monoclonal antibody, thymic stromal lymphopoietin (TSLP) monoclonal antibody, anti-IgE...
- Use of any investigational product within 4 weeks prior to the screening visit or planning to participate in other clinical studies during this study.
- Forced expiratory volume in 1 second (FEV1) ≤ 50% of the predicted value during the screening/run-in period.
- Have acute sinusitis, nasal infection, or upper respiratory tract infection at screening or within 2 weeks prior to screening.
- Have received a live-attenuated vaccine within 12 weeks prior to randomization or planning to receive one during the study.
The study team makes the final eligibility decision.
Where it's taking place
- Beijing, Beijing Municipality, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 12 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Beijing, Beijing Municipality, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.